130 related articles for article (PubMed ID: 20834029)
1. Monitoring of the anticoagulants argatroban and lepirudin: a comparison of laboratory methods.
Ivandic B; Zorn M
Clin Appl Thromb Hemost; 2011 Oct; 17(5):549-55. PubMed ID: 20834029
[TBL] [Abstract][Full Text] [Related]
2. Monitoring of Argatroban and Lepirudin: What is the Input of Laboratory Values in "Real Life"?
Seidel H; Kolde HJ
Clin Appl Thromb Hemost; 2018 Mar; 24(2):287-294. PubMed ID: 28320219
[TBL] [Abstract][Full Text] [Related]
3. Measuring direct thrombin inhibitors with routine and dedicated coagulation assays: which assay is helpful?
Curvers J; van de Kerkhof D; Stroobants AK; van den Dool EJ; Scharnhorst V
Am J Clin Pathol; 2012 Oct; 138(4):551-8. PubMed ID: 23010710
[TBL] [Abstract][Full Text] [Related]
4. Monitoring of argatroban and lepirudin anticoagulation in critically ill patients by conventional laboratory parameters and rotational thromboelastometry - a prospectively controlled randomized double-blind clinical trial.
Beiderlinden M; Werner P; Bahlmann A; Kemper J; Brezina T; Schäfer M; Görlinger K; Seidel H; Kienbaum P; Treschan TA
BMC Anesthesiol; 2018 Feb; 18(1):18. PubMed ID: 29426286
[TBL] [Abstract][Full Text] [Related]
5. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
Warkentin TE; Greinacher A; Craven S; Dewar L; Sheppard JA; Ofosu FA
Thromb Haemost; 2005 Nov; 94(5):958-64. PubMed ID: 16363236
[TBL] [Abstract][Full Text] [Related]
6. Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing.
Gosselin RC; King JH; Janatpour KA; Dager WE; Larkin EC; Owings JT
Ann Pharmacother; 2004 Sep; 38(9):1383-8. PubMed ID: 15238620
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of intravenous direct thrombin inhibitor monitoring tests: Correlation with plasma concentrations and clinical outcomes in hospitalized patients.
Beyer JT; Lind SE; Fisher S; Trujillo TC; Wempe MF; Kiser TH
J Thromb Thrombolysis; 2020 Feb; 49(2):259-267. PubMed ID: 31559512
[TBL] [Abstract][Full Text] [Related]
8. Laboratory Monitoring of Parenteral Direct Thrombin Inhibitors.
Van Cott EM; Roberts AJ; Dager WE
Semin Thromb Hemost; 2017 Apr; 43(3):270-276. PubMed ID: 28052306
[TBL] [Abstract][Full Text] [Related]
9. Monitoring of anticoagulant effects of direct thrombin inhibitors.
Fenyvesi T; Jörg I; Harenberg J
Semin Thromb Hemost; 2002 Aug; 28(4):361-8. PubMed ID: 12244483
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia.
Kiser TH; Jung R; MacLaren R; Fish DN
Pharmacotherapy; 2005 Dec; 25(12):1736-45. PubMed ID: 16305293
[TBL] [Abstract][Full Text] [Related]
11. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time.
Harder S; Graff J; Klinkhardt U; von Hentig N; Walenga JM; Watanabe H; Osakabe M; Breddin HK
Thromb Haemost; 2004 Jun; 91(6):1137-45. PubMed ID: 15175800
[TBL] [Abstract][Full Text] [Related]
12. Anticoagulant activity and pharmacokinetic properties of a sub-cutaneously administered mixed micellar formulation of argatroban in experimental animals.
Berry CN; Lunven C; Lecoffre C; Lainée P; O'Connor SE; André F; Roger B; Garrigou-Gadenne D; Rouchouse A; Roome NO; Vivan N
Thromb Haemost; 2000 Aug; 84(2):278-85. PubMed ID: 10959701
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the aPTT with alternative tests for monitoring direct thrombin inhibitors in patient samples.
Lind SE; Boyle ME; Fisher S; Ishimoto J; Trujillo TC; Kiser TH
Am J Clin Pathol; 2014 May; 141(5):665-74. PubMed ID: 24713737
[TBL] [Abstract][Full Text] [Related]
14. Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban, on prothrombin time and INR values.
Gosselin RC; Dager WE; King JH; Janatpour K; Mahackian K; Larkin EC; Owings JT
Am J Clin Pathol; 2004 Apr; 121(4):593-9. PubMed ID: 15080313
[TBL] [Abstract][Full Text] [Related]
15. Argatroban and lepirudin requirements in a 6-year-old patient with heparin-induced thrombocytopenia.
John TE; Hallisey RK
Pharmacotherapy; 2005 Oct; 25(10):1383-8. PubMed ID: 16185183
[TBL] [Abstract][Full Text] [Related]
16. Responsiveness of the activated partial thromboplastin time and dilute thrombin time to argatroban: Results of an in vitro study.
Scalambrino E; Padovan L; Chantarangkul V; Clerici M; Artoni A; Peyvandi F; Tripodi A
Int J Lab Hematol; 2020 Jun; 42(3):e128-e131. PubMed ID: 32086868
[No Abstract] [Full Text] [Related]
17. Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia.
Dang CH; Durkalski VL; Nappi JM
Pharmacotherapy; 2006 Apr; 26(4):461-8. PubMed ID: 16553503
[TBL] [Abstract][Full Text] [Related]
18. Effect of phenprocoumon on monitoring of lepirudin, argatroban, melagatran and unfractionated heparin with the PiCT method.
Fenyvesi T; Jörg I; Harenberg J
Pathophysiol Haemost Thromb; 2002; 32(4):174-9. PubMed ID: 12759518
[TBL] [Abstract][Full Text] [Related]
19. Trends in parenteral direct thrombin inhibitor use in pediatric patients: analysis of a large administrative database.
Moffett BS; Teruya J
Arch Pathol Lab Med; 2014 Sep; 138(9):1229-32. PubMed ID: 25171706
[TBL] [Abstract][Full Text] [Related]
20. Comparison of monitoring methods for lepirudin: impact of warfarin and lupus anticoagulant.
Salmela B; Joutsi-Korhonen L; Saarela E; Lassila R
Thromb Res; 2010 Jun; 125(6):538-44. PubMed ID: 20181379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
